Home / Stocks / Dishman Carbo Amcis Ltd
DCAL

Dishman Carbo Amcis Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹118.53

Change

-2.62 (-2.16%)

Open

₹121.15

Prev. Close

₹121.15

Day High

₹126.79

Day Low

₹116.6

Volume Analysis

Traded

1,582,141

Delivered

649,678

Delivery %

41.06%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (3)

  • •Trading within 3% of its 52-week low (₹128.0)
  • •Low return on equity (1.58%)
  • •Below-average fundamentals quality score (42/100)

Opportunities (0)

No signal for this stock

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹134.87 ₹130.83 ₹124.68 ₹120.64 ₹114.49 ₹110.45 ₹104.3
Fibonacci ₹130.83 ₹126.94 ₹124.53 ₹120.64 ₹116.75 ₹114.34 ₹110.45
Camarilla ₹121.33 ₹120.4 ₹119.46 ₹120.64 ₹117.6 ₹116.66 ₹115.73

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-53.79%

1 Week

-31.92%

1 Month

-16.59%

3 Months

-31.7%

6 Months

-39.33%

1 Year

-51.85%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹244.17

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

-1.86%

Net margin -4.21% × asset turnover 0.25x × equity multiplier 1.77x

Company Overview

Sector

Healthcare

Market Cap

₹2,183 Cr

P/E (TTM)

151.0

ROE

1.58%

Book Value

₹426.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Dishman Carbo Amcis Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 42/100. The strongest factor is Financial Strength (88/100), while Momentum (8/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week low (₹128.0); low return on equity (1.58%). FII holding has been falling.

TopFund Score — Fundamentals Quality

42/100 — Weak

Data confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

88

Growth

39

Valuation

33

Cash Flow

51

Corporate Governance

56

Momentum

8

Institutional Ownership

17

Business Quality

35

Risk & Volatility

10

Liquidity

71

From Screener.in

  • +Stock is trading at 0.33 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of 8.93% over past five years.
  • −Company has a low return on equity of -0.40% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Audio recording of 16 Nov 2026 earnings call for Q2 FY2026-27 results available on website.

Pls. find enclosed herewith Investor Presentation.

Dishman Carbogen Amcis approved Q2 FY2026-27 results; consolidated net loss Rs124.61 crore, standalone loss Rs49.18 crore.

Pls. find enclosed herewith intimation of Conference Call to be held on 16th November 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 587 651 655 524 789 682 716 708 653 720 851 678 507
Expenses + 526 610 592 495 642 542 564 567 504 607 688 618 461
Operating Profit 61 41 63 29 147 140 153 141 149 113 163 60 46
OPM % 10.0% 6.0% 10.0% 6.0% 19.0% 21.0% 21.0% 20.0% 23.0% 16.0% 19.0% 9.0% 9.0%
Other Income + 5 6 4 -4 4 8 -4 22 8 7 15 16 4
Interest 27 33 31 32 37 49 42 43 42 46 43 37 40
Depreciation 75 80 85 71 72 72 79 81 84 84 89 91 90
Profit before tax -36 -66 -49 -78 42 27 28 39 31 -10 46 -51 -81
Tax % 13.0% -10.0% 42.0% 0.0% 21.0% 83.0% -56.0% 39.0% -114.0% 24.0% 53.0% 13.0% -18.0%
Net Profit + -41 -60 -70 -78 33 5 43 23 65 -13 22 -58 -67
EPS in Rs -3 -4 -4 -5 2 0 3 1 4 -1 1 -4 -4
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -4 2 6 -28 35 5 9 35 -17 5 19 -4 -22

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,031 1,714 1,695 2,059 2,044 1,912 2,141 2,413 2,616 2,712 2,932 2,756
Expenses + 830 1,261 1,249 1,507 1,540 1,638 1,809 2,081 2,329 2,243 2,366 2,374
Operating Profit 201 452 445 552 503 274 331 332 286 469 566 382
OPM % 20.0% 26.0% 26.0% 27.0% 25.0% 14.0% 15.0% 14.0% 11.0% 17.0% 19.0% 14.0%
Other Income + 14 26 46 54 39 16 29 -20 22 4 52 42
Interest 56 49 49 57 62 48 57 86 120 159 174 166
Depreciation 69 214 211 240 283 308 308 281 311 294 339 354
Profit before tax 91 216 231 309 197 -65 -4 -55 -122 19 105 -97
Tax % 12.0% 33.0% 33.0% 32.0% 20.0% 154.0% -524.0% -45.0% 26.0% 83.0% 7.0% —
Net Profit + 80 145 155 210 159 -165 18 -30 -153 3 97 -116
EPS in Rs — — 10 13 10 -11 1 -2 -10 0 6 -7
Dividend Payout % 0.0% 0.0% 0.0% 2.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth — — -1 21 -1 -6 12 13 8 4 8 0

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 863 4,814 5,075 5,347 5,684 5,667 5,518 5,778 5,596 5,800 6,646 6,640
Borrowings + 868 950 1,095 1,042 1,357 1,589 1,830 2,209 2,313 2,389 3,076 3,417
Other Liabilities + 334 811 967 899 1,121 1,068 1,255 1,421 1,631 1,766 2,158 1,708
Total Liabilities 2,081 6,574 7,169 7,321 8,193 8,356 8,634 9,439 9,571 9,987 11,911 11,796
Fixed Assets + 1,012 4,852 5,066 5,098 5,678 5,698 5,773 6,188 6,724 7,055 8,076 8,093
CWIP 307 133 151 175 234 486 780 1,043 646 467 570 292
Investments 1 40 196 167 191 172 324 249 102 97 91 92
Other Assets + 761 1,550 1,757 1,881 2,091 2,000 1,758 1,959 2,098 2,368 3,174 3,319
Total Assets 2,081 6,574 7,169 7,321 8,193 8,356 8,634 9,439 9,571 9,987 11,911 11,796
Equity Capital 16 0 32 32 31 31 31 31 31 31 31 31

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 203 303 226 282 585 513 355 266 379 371 491
Cash from Investing Activity + -231 -107 -297 -169 -442 -380 -619 -494 -225 -192 -245
Cash from Financing Activity + 25 -137 78 -102 -98 -11 130 250 -22 -102 201
Net Cash Flow -3 59 7 11 46 122 -133 22 132 77 447
Free Cash Flow -37 164 22 -26 177 147 -101 -352 76 156 225
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 107 92 58 75 131 206 124 90 139 86 88

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 59.32% → 59.32%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 28.39% 29.63% 31.17% 31.29% 30.51% 29.94% 29.48% 31.23% 31.75% 31.6% 31.76% 32.05%
Promoters 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32%
FII 8.6% 8.7% 8.05% 8.18% 8.75% 9.49% 9.94% 8.07% 7.66% 7.45% 6.86% 6.96%
DII 3.68% 2.36% 1.47% 1.22% 1.42% 1.26% 1.27% 1.37% 1.27% 1.63% 2.06% 1.65%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Dishman Carbo Amcis Ltd (this stock) 2,183 151.0 0.33 1.58%
Sai Parenterals Limited 2,195 88.0 4.44 4.88%
Panacea Biotec Ltd 2,171 — 2.6 -2.42%
Vimta Labs Limited 2,230 36.7 6.46 13.5%
Indoco Remedies Ltd. 2,079 — 2.03 -9.36%
Windlas Biotech Limited 2,067 31.1 3.64 12.2%
Sakar Healthcare Limited 2,319 54.1 6.68 9.99%

Which Mutual Funds Hold Dishman Carbo Amcis Ltd?

Frequently Asked Questions about Dishman Carbo Amcis Ltd

Community Sentiment

What are other investors saying about Dishman Carbo Amcis Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.